MAGELLAN LONGEVITY
HomeResearchStudy library › Glucosamine/Chondroitin and Mortality in a US NHANES Cohort
Study summary · General aging biology & healthspan

Does regular consumption of glucosamine/chondroitin affect overall and cardiovascular (CVD) mortality in US adults?

In one paragraph

Glucosamine + Chondroitin, a survey study in 16,686 participants (Frontiers in Pharmacology 2020, PMID 33219063) — during a median follow-up of 107 months, there were 3366 total deaths (20.17%), with 674 (20.02%) attributed to CVD. The study design was observational, which means it cannot establish a causal link between glucosamine/chondroitin intake and reduced mortality.

Source: Frontiers in Pharmacology 2020, PMID 33219063 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

Frontiers in Pharmacology · 2020 · PMID 33219063 · DOI 10.3122/jabfm.2020.06.200110

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Regular use of glucosamine/chondroitin supplements is associated with a lower risk of death from all causes and cardiovascular disease in US adults.

The question

Does regular consumption of glucosamine/chondroitin affect overall and cardiovascular (CVD) mortality in US adults?

What they tested

Previous studies suggest an association between glucosamine/chondroitin intake and mortality, leading to the hypothesis that regular consumption may be linked to lower mortality rates in a national US sample.

How they did it

This study analyzed combined data from 16,686 participants in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2010, linked with the 2015 Public-use Linked Mortality File. Cox proportional hazards models were used to assess the association between glucosamine/chondroitin use and all-cause and CVD mortality.

What they found

During a median follow-up of 107 months, there were 3366 total deaths (20.17%), with 674 (20.02%) attributed to CVD. Participants taking glucosamine/chondroitin for a year or longer (3.94% of the sample) showed a 39% reduction in all-cause mortality (HR = 0.61) and a 65% reduction in CVD mortality (HR = 0.35) after adjusting for age. After further adjustment for age, sex, race, education, smoking status, and physical activity, the association remained significant, with a 27% reduction in all-cause mortality (HR = 0.73) and a 58% reduction in CVD mortality (HR = 0.42).

Adjusted Reduction in Mortality with Glucosamine/Chondroitin Use
Values shown: Percentage Reduction (%)
All-Cause Mortality (Age-Adjusted)39
CVD Mortality (Age-Adjusted)65
All-Cause Mortality (Multivariable-Adjusted)27
CVD Mortality (Multivariable-Adjusted)58

Percentage reduction in mortality risk associated with regular glucosamine/chondroitin intake, adjusted for various factors.

What it means

Regular intake of glucosamine/chondroitin is associated with lower all-cause and CVD mortality in a national US cohort. These findings are consistent with previous studies in other populations.

Limitations

The study design was observational, which means it cannot establish a causal link between glucosamine/chondroitin intake and reduced mortality. Prospective studies are needed to confirm these findings.

“Glucosamine/chondroitin use was associated with reduced all-cause mortality in a nationally representative U.S. cohort.”— from the published abstract, Frontiers in Pharmacology 2020

The paper at a glance

TitleGlucosamine/Chondroitin and Mortality in a US NHANES Cohort
JournalFrontiers in Pharmacology
Year2020
PMID33219063 ↗
DOI10.3122/jabfm.2020.06.200110 ↗
TopicGeneral aging biology & healthspan

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Glucosamine + Chondroitin (+ MSM)

The evidence for glucosamine and chondroitin in human osteoarthritis is genuinely mixed. The landmark GAIT trial found the pair no better than placebo overall but possibly helpful in the subgroup with moderate-to-severe knee pain, and the MOVES trial found the combination non-inferior to celecoxib;

D-Glucosamine

Evidence on glucosamine for aging-related joint health is genuinely mixed: in the landmark 3-year randomized trial of prescription crystalline glucosamine sulfate (n=212), placebo patients lost significant knee joint space (−0.31 mm) while glucosamine patients did not (−0.06 mm), with symptoms improving on…

D-Glucosamine Sulfate

D-Glucosamine sulfate is a salt of glucosamine, an amino monosaccharide the body synthesizes from…

Check price on Amazon ↗

Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield)

Osteo Bi-Flex Triple Strength is an oral joint-health supplement whose principal ingredients are…

Check price on Amazon ↗

Glucosamine Chondroitin MSM (with OptiMSM)

Glucosamine, chondroitin sulfate, and methylsulfonylmethane (MSM) are naturally occurring compounds…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does regular consumption of glucosamine/chondroitin affect overall and cardiovascular (CVD) mortality in US adults? [Plain-English summary of Frontiers in Pharmacology 2020, PMID 33219063, DOI 10.3122/jabfm.2020.06.200110]. Magellan Longevity. https://magellanlongevity.com/study/glu_nhanes.html
BibTeX
@misc{magellan_glu_nhanes, title = {Does regular consumption of glucosamine/chondroitin affect overall and cardiovascular (CVD) mortality in US adults?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/glu_nhanes.html}}, note = {Plain-English summary of PubMed PMID 33219063; DOI 10.3122/jabfm.2020.06.200110; Frontiers in Pharmacology 2020. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/glu_nhanes.html

Related studies in the Magellan library

All 25 Magellan summaries on general aging biology & healthspan →

How this summary was made. Every section above restates what the published abstract of PMID 33219063 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.